ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial

Study limitation reported by the research below: “The trial enrolled almost exclusively Asian patients (90% Chinese, 10% Japanese), which may limit applicability to non-Asian populations.”

Papers